CHP
INFI

Cable Hill Partners’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Cable Hill Partners’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-100
Closed – – 973
2017
Q4 		$0 Buy
+100
New +$207 ﹤0.01% 1039

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Cable Hill Partners's INFI Position: Q1 2018 in Review

Cable Hill Partners sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2018, closing a stake of 100 shares.

Cable Hill Partners first reported a position in INFI in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 66 funds tracked by Wall St. Rank hold INFI as of Q1 2018.

  • Cable Hill Partners reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Cable Hill Partners sold 100 Infinity Pharmaceuticals, Inc. shares in Q1 2018.
  • Cable Hill Partners first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
  • Cable Hill Partners's Infinity Pharmaceuticals, Inc. position peaked at $0 in Q4 2017.
  • 66 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2018.

Based on Cable Hill Partners's 13F filing for Q1 2018, filed 20 Apr 2018.